Sells non-opioid pain medicines and a handheld cold-treatment device for postsurgical and knee pain to healthcare providers.
10-K for FY2025, filed Feb 26, 2026Our mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients. We have three commercialized non-opioid…View ↗
The iovera° system is a non-opioid handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature to targeted…View ↗
We have built our sales and marketing organization to commercialize our products. Our primary target audiences are healthcare practitioners…View ↗
Hospitals, surgery centers and provider offices order EXPAREL through wholesalers, while ZILRETTA goes mainly to specialty distributors and pharmacies; product sales are counted when transferred, and customers generally pay within zero to four months.
10-K for FY2025, filed Feb 26, 2026
$726.4M
10-K for FY2025, filed Feb 26, 2026
$726.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
100%
FY2022: 100%
|
Net product sales, FY2025
$722.9M Sources
|
Sold outright |
|
Royalty revenue
|
0.5%
FY2022: 0.4%
|
Royalty revenue, FY2025
$3.6M Sources
|
Hospitals, surgery centers and provider offices order EXPAREL through wholesalers, which drop-ship to end users; ZILRETTA is sold mainly through specialty distributors and pharmacies to physicians, clinics and medical centers or hospitals. Pacira also contracts directly with healthcare providers and intermediaries such as group purchasing organizations.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug…View ↗
Yes. It kept 1 cent of every revenue dollar as net income in FY2025 and turned 19 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Nov 5, 2026
As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into the…View ↗
8-K, filed Oct 8, 2026
Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, as promptly as practicable (but in no event more…View ↗
8-K, filed Jun 30, 2026
Pursuant to the Purchase Agreement, the Company has agreed to divest to the Purchaser (i) all of the issued and outstanding capital stock…View ↗
Growing. Revenue grew 34% in 4 years, from $541.5M in FY2021 to $726.4M in FY2025, about 8% a year.
Gene therapy development
The knee osteoarthritis gene therapy has moved from an early human study to a later stage of clinical testing.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026Advancing our clinical-stage pipeline within multiple areas of unmet need. We have completed a Phase 1 study of PCRX-201, a novel, IA gene…View ↗
Our mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients. We have three commercialized non-opioid…View ↗
Competes with Avanos Medical
10-K for FY2025, filed Feb 26, 2026Besides pharmaceutical products for pain management, iovera° competes with medical devices that ablate or degenerate peripheral nerves to…View ↗
Loading...